AbCheck Antibody Discovery Agreement with U3 Pharma
(Thomson Reuters ONE) -
AbCheck s.r.o. /
AbCheck Antibody Discovery Agreement with U3 Pharma
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Plzen, Czech Republic; February 18th, 2013: AbCheck s.r.o., the multi antibody
discovery platforms company, announced today that it has entered into a research
collaboration with U3 Pharma GmbH, based in Martinsried, Germany. U3 Pharma is
the antibody targeted cancer drug development affiliate of Daiichi Sankyo Co.
Ltd., one of the top 20 leading pharmaceutical companies worldwide.
Under the agreement AbCheck will use its AbSieve discovery platform, which
combines the Company's proprietary phage and yeast display technologies, to
deliver antibodies against an undisclosed number of U3 Pharma targets. U3
Pharma, which has full rights to any antibodies selected, will pay AbCheck
discovery fees and milestone payments. Other financial and deal terms are not
disclosed.
"The selection of AbCheck by U3 Pharma is very important to us," said Dr. Volker
Lang, Managing Director of AbCheck. "Entering into a research collaboration with
the Company, a recognized specialist in innovative antibody-based therapeutics,
further underlines the quality of AbCheck's antibody discovery technologies and
efficient processes that ensure the delivery of high quality GMP ready
antibodies. Furthermore, this deal once again validates our exceptional business
model, which has now been proven through partnerships with both pharma and
biotech companies throughout the US and Europe."
Dr. Shoji Hirashima, CEO and Managing Director of U3 Pharma said: "AbCheck has a
well-established technology-platform and defined processes for antibody drug
discovery. We believe we will identify good drug candidate antibodies more
efficiently through this collaboration with AbCheck."
About AbCheck
AbCheck s.r.o. focuses on the discovery and/or optimization of human antibodies
for partner companies. AbSieve, the combined phage and yeast display platforms,
is used to develop antibodies in all antibody formats including full length IgGs
as well as customer specific and novel antibody formats. AbAccel, a proprietary
algorithm for affinity maturation and optimization, is combined with Phage or
Yeast Display and addresses affinity maturation, developability and stability
optimization of antibodies in just one step. Antibodies generated by AbCheck's
AbSieve and AbAccel platforms have extremely high specificities and affinities,
they are "GMP ready" and have improved drugability. Furthermore, the use of
Yeast display allows the screening in the final antibody drug format. AbCheck
has entered into several partnerships and is recognized for its expertise in
antibody discovery throughout the US and Europe.
About U3 Pharma
U3 Pharma GmbH, based in Martinsried near Munich, Germany, is a leader in
targeted cancer drug development. Established in July 2001, the company has
produced a pipeline of novel targeted therapeutics based on the ground-breaking
discoveries made by its founder - Professor Axel Ullrich.
Since May 2008, U3 Pharma has been an affiliate of Daiichi Sankyo Co. Ltd., one
of the top 20 leading pharmaceutical companies worldwide and No. 3 in Japan.
Being part of this global environment, U3 Pharma is striving to provide patients
around the world with innovative antibody-based therapeutics.
About Daiichi Sankyo
The Daiichi Sankyo Group is dedicated to the creation and supply of innovative
pharmaceutical products to address the diversified, unmet medical needs of
patients in both mature and emerging markets. While maintaining its portfolio
of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial
infections, the Group is engaged in the development of treatments for thrombotic
disorders and focused on the discovery of novel oncology and cardiovascular-
metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid
Business Model," which will respond to market and customer diversity and
optimize growth opportunities across the value chain. For more information,
please visit www.daiichisankyo.com.
For further information:
AbCheck s.r.o. MC Services AG
Dr. Volker Lang Anne Hennecke
Managing Director Managing Partner
Phone: +420 378 051500 Phone: +49 89 210 228 18
Fax: +420 378 051506 Fax: +49 89 210 228 88
Email: V.Lang(at)abcheck.eu Email: anne.hennecke(at)mc-services.eu
Press Release (PDF):
http://hugin.info/143842/R/1678934/548127.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: AbCheck s.r.o. via Thomson Reuters ONE
[HUG#1678934]
Unternehmensinformation / Kurzprofil:
Datum: 18.02.2013 - 10:25 Uhr
Sprache: Deutsch
News-ID 230344
Anzahl Zeichen: 5699
contact information:
Town:
Plzen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 173 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"AbCheck Antibody Discovery Agreement with U3 Pharma"
steht unter der journalistisch-redaktionellen Verantwortung von
AbCheck s.r.o. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
